Unicycive Therapeutics (NASDAQ:UNCY) and Arvinas (NASDAQ:ARVN) Head-To-Head Review

Unicycive Therapeutics (NASDAQ:UNCY) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Profitability

This table compares Unicycive Therapeutics and Arvinas’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	N/A	-29.88%
Arvinas	N/A	-50.26%	-24.87%

Institutional & Insider Ownership

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 24.1% of Unicycive Therapeutics shares are held by insiders. Comparatively, 5.2% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Unicycive Therapeutics and Arvinas”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680,000.00	106.85	-$30.54 million	($0.97)	-0.72
Arvinas	$78.50 million	16.62	-$367.30 million	($4.67)	-4.07

Unicycive Therapeutics has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Unicycive Therapeutics and Arvinas, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	0	0	4	1	3.20
Arvinas	0	1	14	0	2.93

Unicycive Therapeutics currently has a consensus target price of $5.13, suggesting a potential upside of 632.14%. Arvinas has a consensus target price of $63.50, suggesting a potential upside of 234.39%. Given Unicycive Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Unicycive Therapeutics is more favorable than Arvinas.

Risk and Volatility

Unicycive Therapeutics has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500.

Summary

Unicycive Therapeutics beats Arvinas on 10 of the 14 factors compared between the two stocks.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

About Arvinas

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.